Pulmonary Arterial Hypertension News and Research

RSS
Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Study identifies two proteins involved in toxin-related pulmonary hypertension

Study identifies two proteins involved in toxin-related pulmonary hypertension

Review explores intrinsic mechanisms driving right ventricular remodeling in pulmonary arterial hypertension

Review explores intrinsic mechanisms driving right ventricular remodeling in pulmonary arterial hypertension

Faulty cellular recycling may link pulmonary arterial hypertension to brain damage

Faulty cellular recycling may link pulmonary arterial hypertension to brain damage

County analysis reveals deep geographic and racial heart disease disparities

County analysis reveals deep geographic and racial heart disease disparities

Researchers identify a rare genetic change linked to neurodevelopmental disorder

Researchers identify a rare genetic change linked to neurodevelopmental disorder

Blocking a naturally occurring molecule reverses deadly lung disease in preclinical models

Blocking a naturally occurring molecule reverses deadly lung disease in preclinical models

New findings highlight risks and therapeutic targets in systemic sclerosis

New findings highlight risks and therapeutic targets in systemic sclerosis

Qureight establishes Scientific Advisory Board focused on pulmonary hypertension

Qureight establishes Scientific Advisory Board focused on pulmonary hypertension

Tiny organism offers insight into neurological side effects of chemotherapy

Tiny organism offers insight into neurological side effects of chemotherapy

Sotatercept shows strong benefits for newly diagnosed pulmonary hypertension patients

Sotatercept shows strong benefits for newly diagnosed pulmonary hypertension patients

Pediatric lung transplantation shows promising outcomes in China

Pediatric lung transplantation shows promising outcomes in China

New ESC guidelines prioritize women's autonomy in high-risk pregnancies

New ESC guidelines prioritize women's autonomy in high-risk pregnancies

Early clinical events predict disease progression in very early systemic sclerosis

Early clinical events predict disease progression in very early systemic sclerosis

New screening tool enhances early detection of pulmonary hypertension

New screening tool enhances early detection of pulmonary hypertension

New therapy shows dramatic survival benefits in advanced pulmonary arterial hypertension

New therapy shows dramatic survival benefits in advanced pulmonary arterial hypertension

Promising findings for the treatment of patients with pulmonary arterial hypertension with a high risk of mortality

Promising findings for the treatment of patients with pulmonary arterial hypertension with a high risk of mortality

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Women experience higher waiting-list mortality in lung transplantation

Women experience higher waiting-list mortality in lung transplantation

Pharmacy benefit managers steer Medicare patients to use their own pharmacies

Pharmacy benefit managers steer Medicare patients to use their own pharmacies

Vitamin D receptor activation slows cell overgrowth in pulmonary hypertension

Vitamin D receptor activation slows cell overgrowth in pulmonary hypertension

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.